June 2023 tender notification
Pharmac is pleased to provide the latest tender results
Download the tender notification [PDF 76 KB]
Tender results
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2021/22 Invitation to Tender, dated 1 November 2021 and the 2022/23 Invitation to Tender, dated 31 October 2022.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 July 2023 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2021/22 Tender – Principal Supply Status applies until 30 June 2025
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows (amendments to presentation in bold):
1. Tenders awarded to pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Budesonide |
Cap modified-release 3 mg; 90 capsule bottle |
$166.50 |
$87.60 |
Budesonide Te Arai |
1 November 2023 |
1 April 2024 |
Entocort CIR (Pharmacodes 2272547 and 2536528) (Chiesi) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
The decisions were as follows (amendments to presentation in bold):
2. Tenders awarded to currently listed Pharmaceuticals where no other brand is listed
|
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
DV |
Date of price change |
Principal Supply date |
|---|---|---|---|---|---|---|---|---|
|
Budesonide |
Cap modified-release 3 mg; 90 capsule bottle |
$166.50 |
$87.60 |
Budesonide Te Arai (Te Arai) |
5% |
1 November 2023 |
1 April 2024 |
|
3. Tenders awarded to currently listed Pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Daptomycin |
Inj 500 mg vial; 1 vial pack |
$243.52 |
$115.36 |
Daptomycin Dr Reddy’s (Dr Reddy’s) |
5% |
1 August 2023 |
1 January 2024 |
Cubicin (MSD) |
2022/23 Tender – Principal Supply Status applies until 30 June 2026
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
4. Tenders awarded to pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Allopurinol |
Tab 100 mg; 1000 tablet bottle |
$11.47 (500 tablet bottle) |
$17.99 |
Ipca-Allopurinol (Miro) |
1 January 2024 |
1 June 2024 |
DP-Allopurinol (Douglas) |
|
Allopurinol |
Tab 300 mg; 500 tablet bottle |
$28.57 |
$22.50 |
Ipca-Allopurinol (Miro) |
1 January 2024 |
1 June 2024 |
DP-Allopurinol (Douglas) |
|
Donepezil hydrochloride1 |
Tab 5 mg; 84 tablet blister pack |
$4.34 (90 tablet blister pack) |
$3.70 |
Ipca-Donepezil |
1 January 2024 |
1 June 2024 |
Donepezil-Rex (Rex Medical) |
|
Donepezil hydrochloride1 |
Tab 10 mg; 84 tablet blister pack |
$6.64 (90 tablet blister pack) |
$5.50 |
Ipca-Donepezil |
1 January 2024 |
1 June 2024 |
Donepezil-Rex (Rex Medical) |
|
Febuxostat |
Tab 80 mg; 28 tablet blister pack |
$20.00 |
$4.73 |
Febuxostat (Teva) |
1 January 2024 |
1 June 2024 |
Febuxostat multichem (Multichem) |
|
Febuxostat |
Tab 120 mg; 28 tablet blister pack |
$20.00 |
$11.78 |
Febuxostat (Teva) |
1 January 2024 |
1 June 2024 |
Febuxostat multichem (Multichem) |
|
1Brand switch fee of $4.50 is payable for this product from 1 June 2024 to 31 August 2024 |
|||||||
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
5. Tenders awarded to Pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Allopurinol |
Tab 100 mg; 1000 tablet bottle |
$11.47 (500 tablet bottle) |
$17.99 |
Ipca-Allopurinol (Miro) |
5% |
1 January 2024 |
1 June 2024 |
DP-Allopurinol (Douglas) |
|
Allopurinol |
Tab 300 mg; 500 tablet bottle |
$28.57 |
$22.50 |
Ipca-Allopurinol (Miro) |
5% |
1 January 2024 |
1 June 2024 |
DP-Allopurinol (Douglas) |
|
Donepezil hydrochloride |
Tab 5 mg; 84 tablet blister pack |
$4.34 (90 tablet blister pack) |
$3.70 |
Ipca-Donepezil |
5% |
1 January 2024 |
1 June 2024 |
Donepezil-Rex (Rex Medical) |
|
Donepezil hydrochloride |
Tab 10 mg; 84 tablet blister pack |
$6.64 (90 tablet blister pack) |
$5.50 |
Ipca-Donepezil |
5% |
1 January 2024 |
1 June 2024 |
Donepezil-Rex (Rex Medical) |
|
Febuxostat |
Tab 80 mg; 28 tablet blister pack |
$20.00 |
$4.73 |
Febuxostat (Teva) |
5% |
1 January 2024 |
1 June 2024 |
Febuxostat multichem (Multichem) |
|
Febuxostat |
Tab 120 mg; 28 tablet blister pack |
$20.00 |
$11.78 |
Febuxostat (Teva) |
5% |
1 January 2024 |
1 June 2024 |
Febuxostat multichem (Multichem) |
Tender declines - Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the:
- 2020/21 Invitation to Tender dated 2 November 2020
- 2021/22 Invitation to Tender dated 1 November 2021
- 2022/23 Invitation to Tender dated 31 October 2022
2020/21 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Baclofen |
Tab 10 mg |
|
Brimonidine tartrate with timolol maleate |
Eye drops 0.2% with timolol maleate 0.5% |
|
Carboplatin |
Inj 10 per ml, 45 ml |
|
Chlorhexidine gluconate |
Mouthwash 0.2% |
|
Hydroxychloroquine sulphate |
Tab 200 mg |
|
Lanreotide |
Inj 60 mg per 0.5 ml, 0.5 ml syringe |
|
Lanreotide |
Inj 90 mg per 0.5 ml, 0.5 ml syringe |
|
Lanreotide |
Inj 120 mg per 0.5 ml, 0.5 ml syringe |
|
Methotrexate |
Inj 7.5 mg prefilled syringe |
|
Methotrexate |
Inj 10 mg prefilled syringe |
|
Methotrexate |
Inj 15 mg prefilled syringe |
|
Methotrexate |
Inj 20 mg prefilled syringe |
|
Methotrexate |
Inj 25 mg prefilled syringe |
|
Methotrexate |
Inj 30 mg prefilled syringe |
|
Terlipressin |
Inj 0.2 mg per ml, 5 ml |
|
Terlipressin |
Inj 1 mg per 8.5 ml ampoule |
2021/22 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Oxybutynin |
Tab 5 mg |
2022/23 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Allopurinol (febuxostat funded without restrictions) |
Tab 100 mg |
|
Allopurinol (febuxostat funded without restrictions) |
Tab 300 mg |
|
Febuxostat (widened access) |
Tab 80 mg |
|
Febuxostat (widened access) |
Tab 120 mg |
|
Ketamine |
Inj 100 mg per ml, 2 ml |
|
Levodopa with carbidopa |
Tab 100 mg with carbidopa 25 mg |
|
Levodopa with carbidopa |
Tab 250 mg with carbidopa25 mg |
|
Levodopa with carbidopa |
Tab long-acting 200 mg with carbidopa 50 mg |
|
Paracetamol |
Inj 10 per ml, 100 ml |
|
Pyridostigmine bromide |
Tab 60 mg |
|
Sacubitril with valsartan (current access) |
Tab 24.3 mg with valsartan 25.7 mg |
|
Sacubitril with valsartan (current access) |
Tab 48.6 mg with valsartan 51.4 mg |
|
Sacubitril with valsartan (current access) |
Tab 97.2 mg with valsartan 102.8 mg |
|
Sacubitril with valsartan (widened access) |
Tab 24.3 mg with valsartan 25.7 mg |
|
Sacubitril with valsartan (widened access) |
Tab 48.6 mg with valsartan 51.4 mg |
|
Sacubitril with valsartan (widened access) |
Tab 97.2 mg with valsartan 102.8 mg |
|
Timolol |
Eye drops 0.5%, gel forming |
Tender decisions on all products included in the 2020/21 Invitation to Tender have now all been announced.
For products included in the 2021/22 and 2022/2023 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.